Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Glioblastoma
and you are
between 18 and 70
years old
0
This is an early phase trial to investigate
how or whether the drug affects your body.
Show me locations

The purpose

This is an open-label positron emission tomography/near infrared (PET/NIRF) study to investigate the imaging navigation performance and evaluation efficacy of dual modality imaging probe 68Ga-BBN-IRDye800CW in glioblastoma (GBM) patients. A single dose of 40μg/111-148 Mega-Becquerel (MBq) and 1.0 mg/ml 68Ga-BBN-IRDye800CW will be injected intravenously before the operation and intraoperative respectively. Visual and semiquantitative method will be used to assess the PET images and real-time margins localization for surgical navigation.

Provided treatments

  • Drug: 68Ga-BBN-IRDye800CW
  • Device: PET/NIRF
  • Procedure: PET/NIR fluorescent imaging-guided surgery
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02910804. The sponsor of the trial is Beijing Tiantan Hospital and it is looking for 30 volunteers for the current phase.
Official trial title:
PET-NIRF Dual Modality Imaging Guiding Surgery in Patients With Glioblastoma